Ceryvyn Therapeutics Limited

CYV · AU · Healthcare / Biotechnology

0.011AUD+0.00 (+22.22%)

Price History

Full chart

Market Stats

Previous Close0.009

Open0.01

Day Range0.009 – 0.011

52-Week Range0.008 – 0.60

Volume1.42M

Market Cap15.05M

P/E (TTM)0.05

Forward P/E6.75

EPS0.24

Dividend Yield0.00%

Beta1.49

50-Day Avg0.0109

200-Day Avg0.3413

About

Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Hawthorn East, Australia.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Headquarters117 Camberwell Road, Hawthorn East, VIC, Australia, 3123, Australia
Websitehttps://ceryvyn.com

Leadership

Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.Executive Chair & CEO · b. 1953
Mr. Hamish GeorgeCFO & Joint Company Secretary
Dr. Stuart MudgeChief Operating Officer
Dr. Michael Gerometta Ph.D.Chief Technology Officer · b. 1964
Ms. Rebbecca WilcoxSenior VP of Preclinical and Translational Science
Ms. Stephanie VipondJoint Company Secretary

Financials

Income Statement

Currency: AUD	2022-06-30	2023-06-30	2024-06-30	2025-06-30	2026-06-30
Total Revenue	90.68K	163.16K	187.01K	39.00K	1.00K
Growth (%)	-	+79.92%	+14.62%	-79.15%	-97.44%
Cost of Revenue	131.79K	252.03K	-	-	-
Gross Profit	-41.10K	-88.26K	-	-	-
Gross Margin	-45.33%	-54.09%	-	-	-
Operating Expense	96.50M	226.56M	-	-	-
Operating Income	-96.54M	-226.65M	-287.02M	-236.44M	-11.95M
Operating Margin	-106456.52%	-138912.04%	-153473.60%	-606264.10%	-1194700.00%
EBITDA	-	-203.77M	-298.16M	-189.76M	341.30M
EBITDA Margin	-	-124892.59%	-159430.40%	-486556.41%	34129500.00%
Net Income	-92.82M	-215.31M	-329.51M	-251.15M	330.44M
Net Income Margin	-102353.66%	-131963.89%	-176193.60%	-643964.10%	33044500.00%
R&D	81.45M	194.62M	263.80M	193.79M	2.21M
R&D as % of Total Revenue	89813.79%	119285.19%	141060.80%	496907.69%	220500.00%
Interest Expense	0	20.34M	45.28M	71.97M	11.06M
Interest Expense % of Total Revenue	0.00%	12464.81%	24210.40%	184551.28%	1105900.00%

Balance Sheet

Currency: AUD	2022-06-30	2023-06-30	2024-06-30	2025-06-30	2026-06-30
Total Assets	60.05M	149.02M	282.45M	86.70M	31.93M
Total Liabilities	12.07M	157.86M	395.87M	393.61M	2.32M
Total Equity	47.98M	-8.84M	-113.42M	-306.91M	29.61M
Cash	44.63M	134.74M	258.04M	73.94M	30.02M

Cash Flow

Currency: AUD	2022-06-30	2023-06-30	2024-06-30	2025-06-30	2026-06-30
Operating Cash Flow	-71.33M	-120.61M	-161.02M	-	-
Financing Cash Flow	171.60K	167.28M	243.73M	34.77M	-30.89M
Capital Expenditure	16.91K	22.00K	33.00K	13.00K	0
Free Cash Flow	-71.35M	-120.63M	-161.05M	-158.66M	-12.50M
FCF to OCF	100.02%	100.02%	100.02%	-	-

Key Statistics & Ratios

Market Cap15.05M

Enterprise Value53.05M

Trailing P/E0.05

Forward P/E6.75

Price / Sales15047.76

Price / Book0.42

EPS0.24

Book Value0.022

Revenue (TTM)1.00K

Gross Profit (TTM)1.00K

EBITDA-11.94M

Profit Margin33044500.00%

Operating Margin-1194700.00%

Return on Equity0.00%

Return on Assets-12.59%

Shares Outstanding1.37B

Shares Float1.12B

Beta1.49

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Dividends

20041×

0.10Oct 11, 2004

Stock Splits

Nov 6, 19893:2
Jun 26, 19891.0554:1